That particular combo trial with Astra is not as important now, given ADXS is doing a potential Phase 3 combo trial with ADXS, however, if for some reason the FDA thinks LLM in combination with PD1 is unsafe, that would be a problem. From reading some other posts, it sounds that Astras PD1 is known to have had some issues with respiratory problems with patients, while our LLM has not. But my point is no one's would likely rush to sign a deal to buy the company until the FDA says the issue is resolved.